[stock_market_widget type=”card” template=”basic2″ assets=”ADCT” realtime=”true” api=”yahoo-finance”]
Biotech companies often face a defining moment when their most important clinical trial results arrive. This is especially true for companies working on cancer treatments where patients have limited options. ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biotechnology company headquartered in Lausanne, Switzerland that focuses on antibody drug conjugates, which are a specialized type of cancer therapy that combines an antibody with a potent drug payload to target cancer cells more precisely. The company’s work centers primarily on hematologic malignancies, which are blood cancers including various types of lymphoma and leukemia, and they are also exploring applications in solid tumors.
The company’s lead product is ZYNLONTA®, which targets relapsed or refractory large B-cell lymphoma after patients have received two or more prior treatments. This condition, particularly diffuse large B-cell lymphoma or DLBCL, is an aggressive form of non-Hodgkin lymphoma that returns or does not respond to initial therapy. Patients with this disease face difficult choices since standard treatments often fail, and options like CAR-T therapy are not accessible to everyone or may not work for them.
The LOTIS-5 Phase 3 trial evaluated whether adding rituximab to ZYNLONTA would improve outcomes compared to R-GemOx, a standard chemotherapy combination for patients with relapsed or refractory DLBCL. The trial met its primary endpoint, demonstrating improved progression-free survival with a hazard ratio of 0.73 and a p-value of 0.008. Patients receiving ZYNLONTA plus rituximab had a median progression-free survival of 6.1 months compared to 4.7 months for those on R-GemOx. The overall response rate reached 58.1% versus 45.2% for the control group, and the complete response rate was 39.5% compared to 26.7%. Importantly, the treatment showed no detrimental effect on overall survival, and patients achieving complete response had better long-term outcomes with 48.5% remaining in complete remission at 24 months versus 16.7% in the control arm.
Despite these positive efficacy results, the stock opened this morning down more than 53% in early trading today, with shares falling to approximately $1.55. This dramatic decline reflects investor concerns about the safety profile rather than the efficacy data. The trial revealed that serious adverse events were higher in the ZYNLONTA arm at 49.0% compared to 34.5% in the control group. More concerning was the rate of Grade 5 events, which are fatal adverse events, at 13.2% in the ZYNLONTA group versus 4.6% in the control group. The company noted that most of these Grade 5 events occurred in patients aged 75 years or older.
The company plans to hold a pre-sBLA meeting with the U.S. FDA in August 2026 and intends to submit a supplemental Biologics License Application in the fourth quarter of 2026. This filing would seek full approval for the combination therapy in the second-line setting for DLBCL, which would expand ZYNLONTA’s current accelerated approval that covers third-line treatment or later. The company also disclosed it is evaluating value-maximizing and cost-reduction options, which many investors interpret as a signal that the board may be open to a potential sale of the company.
ADC Therapeutics represents a small-cap biotech at a critical juncture. The benefit-risk profile of this combination will likely be the focus of intense scrutiny during FDA review, and the outcome could determine whether the company transforms its commercial position or faces significant regulatory challenges.
